Home / Market News / $RANI

$RANI news and market catalysts

The 4 most recent market catalysts affecting $RANI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

4 catalysts 1 high impact 2 bullish 0 bearish Biotechnology
Nov 10, 2026 Corporate Catalyst Neutral Impact 65
Rani Therapeutics Reports Third Quarter 2026 Financial Results
Rani Therapeutics' Q3 2026 financial results show a cash position of $45.3 million, which the company projects will fund operations through the end of 2027. This provides a clear r…
Oct 5, 2026 Corporate Catalyst Bullish Impact 65
Rani Therapeutics Joins FDA Emerging Technology Platform
Rani Therapeutics' RaniPill Capsule platform being accepted into the FDA's Emerging Technology Program is a positive development. This program is designed to facilitate the develop…
Aug 18, 2026 Corporate Catalyst Neutral Impact 65
Chardan Capital Initiates Coverage On Rani Therapeutics Hldgs with Buy Rating, Announces Price Target of $6
Chardan Capital's initiation of coverage on Rani Therapeutics Holdings with a 'Buy' rating and a $6 price target is a positive development for the company. Analyst coverage, especi…
Aug 13, 2026 Corporate Catalyst Bullish Impact 85
Rani Therapeutics Hldgs Q2 EPS $(0.04) Beats $(0.05) Estimate, Sales $1.708M Beat $925.000K Estimate
Rani Therapeutics Holdings (RANI) announced Q2 earnings that surpassed analyst expectations on both the top and bottom lines. The company reported a loss of $(0.04) per share, beat…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.